Medical Market Report

Global Antibacterial Drug Resistance Market By Type (Telavancin (Vibativ), Ceftaroline Fosamil (Teflaro/ Zinforo), Fidaxomicin (Dificid / Dificlir), Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio), Dalbavancin (Dalvance/ Xydalba), Tedizolid Phosphate (Sivextro), Oritavancin (Orbactiv/ Nuvocid), Ceftolozane-Tazobactam (Zerbaxa), Ceftazidime-Avibactam (Avycaz/ Zavicefta), and PHASE III DRUGS), By Application (Gram-Positive, and Gram-Negative), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 137890
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Antibacterial Drug Resistance Market is estimated to be valued US$ XX.X million in 2019. The report on Antibacterial Drug Resistance Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global antibacterial drug resistance market is segmented on the basis of Type, Application, and geography.

    In 2019, the North America market is valued US$ XX.X million and the market share is estimated X.X%, and it is expected to be US$ XX.X million and X.X% in 2029, with a CAGR X.X% from 2020 to 2029.

    Antibacterial Drug Resistance Market Scope:

    By type, the market is segmented into Telavancin (Vibativ), Ceftaroline Fosamil (Teflaro/ Zinforo), Fidaxomicin (Dificid / Dificlir), Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio), Dalbavancin (Dalvance/ Xydalba), Tedizolid Phosphate (Sivextro), Oritavancin (Orbactiv/ Nuvocid), Ceftolozane-Tazobactam (Zerbaxa), Ceftazidime-Avibactam (Avycaz/ Zavicefta), and PHASE III DRUGS. By Application, the market is divided into Gram-Positive, and Gram-Negative.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include AAIPharma Services, ANTABIO, Abgentis, Abbott Laboratories, Absynth Biologics, Achaogen, Acino Holdings, Aventis Pharma, Austell Laboratories, Assembly Biosciences, Arpida, Demuris, Evolva Holding, ContraFect, Cerexa, GSK, InterMune, Isis Pharmaceuticals, Lyndra, and Microbecide.

    Key Market Segments

    Type

    Telavancin (Vibativ)

    Ceftaroline Fosamil (Teflaro/ Zinforo)

    Fidaxomicin (Dificid / Dificlir)

    Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)

    Dalbavancin (Dalvance/ Xydalba)

    Tedizolid Phosphate (Sivextro)

    Oritavancin (Orbactiv/ Nuvocid)

    Ceftolozane-Tazobactam (Zerbaxa)

    Ceftazidime-Avibactam (Avycaz/ Zavicefta)

    PHASE III DRUGS

    Application

    Gram-Positive

    Gram-Negative

    Key Market Players included in the report:

    AAIPharma Services

    ANTABIO

    Abgentis

    Abbott Laboratories

    Absynth Biologics

    Achaogen

    Acino Holdings

    Aventis Pharma

    Austell Laboratories

    Assembly Biosciences

    Arpida

    Demuris

    Evolva Holding

    ContraFect

    Cerexa

    GSK

    InterMune

    Isis Pharmaceuticals

    Lyndra

    Microbecide

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Antibacterial Drug Resistance Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Antibacterial Drug Resistance Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Antibacterial Drug Resistance Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Antibacterial Drug Resistance Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Antibacterial Drug Resistance Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Antibacterial Drug Resistance Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Antibacterial Drug Resistance sub-markets, depending on key regions (various vital states).
    To analyze Antibacterial Drug Resistance Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Antibacterial Drug Resistance Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Antibacterial Drug Resistance Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Antibacterial Drug Resistance Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global Antibacterial Drug Resistance Market Overview
    

    3.1. Antibacterial Drug Resistance Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy4. Global Antibacterial Drug Resistance Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Antibacterial Drug Resistance Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Telavancin (Vibativ)
    

      4.4. Ceftaroline Fosamil (Teflaro/ Zinforo)
    

      4.5. Fidaxomicin (Dificid / Dificlir)
    

      4.6. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
    

      4.7. Dalbavancin (Dalvance/ Xydalba)
    

      4.8. Tedizolid Phosphate (Sivextro)
    

      4.9. Oritavancin (Orbactiv/ Nuvocid)
    

      4.10. Ceftolozane-Tazobactam (Zerbaxa)
    

      4.11. Ceftazidime-Avibactam (Avycaz/ Zavicefta)
    

      4.12. PHASE III DRUGS5. Global Antibacterial Drug Resistance Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Antibacterial Drug Resistance Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Gram-Positive
    

      5.4. Gram-Negative6. Global Antibacterial Drug Resistance Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Antibacterial Drug Resistance Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Antibacterial Drug Resistance Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Antibacterial Drug Resistance Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Antibacterial Drug Resistance Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Antibacterial Drug Resistance Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global Antibacterial Drug Resistance Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. AAIPharma Services
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4. ANTABIO
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Abgentis
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6. Abbott Laboratories
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Absynth Biologics
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8. Achaogen
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Acino Holdings
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10. Aventis Pharma
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. Austell Laboratories
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12. Assembly Biosciences
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments  7.13. Arpida
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments  7.14. Demuris
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments  7.15. Evolva Holding
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments  7.16. ContraFect
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments  7.17. Cerexa
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments  7.18. GSK
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments  7.19. InterMune
    

        7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments  7.20. Isis Pharmaceuticals
    

        7.20.1. Company Overview
    
    7.20.2. Financial Highlights
    
    7.20.3. Product Portfolio
    
    7.20.4. SWOT Analysis
    
    7.20.5. Key Strategies and Developments  7.21. Lyndra
    

        7.21.1. Company Overview
    
    7.21.2. Financial Highlights
    
    7.21.3. Product Portfolio
    
    7.21.4. SWOT Analysis
    
    7.21.5. Key Strategies and Developments  7.22. Microbecide
    

        7.22.1. Company Overview
    
    7.22.2. Financial Highlights
    
    7.22.3. Product Portfolio
    
    7.22.4. SWOT Analysis
    
    7.22.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.